DOI: https://doi.org/10.24959/cphj.19.1481

The pharmacoeconomic analysis of medicines affecting the bone structure and mineralization

N. O. Matiashova, O. O. Gerasymova

Abstract


Osteoporosis is the most common metabolic disease of bones and is characterized by decrease of bone strength, which leads to a high risk of fractures. The seriousness of this disease is in its prolonged asymptomatic course; moreover, the disease affects a significant part of the population, especially older age groups.

Aim. To conduct the pharmacoeconomic analysis of the use of bisphosphonates in patients with postmenopausal osteoporosis by the cost-effectiveness method.

Materials and methods. The cost-effectiveness ratio was calculated. The average retail prices of medicines for 2017 obtained according to the data of the PharmXplorer analytical system of “Morion” company were used to calculate the cost of osteoporosis pharmacotherapy.

Results. Analysis of the cost of treatment showed that Alendon-70 (Micro Labs) was the cheapest drug in the alendronic acid group; its cost per treatment course for three years was 1092 UAH. Ibandronic acid-Vista, 150 mg, (Mistral Capital Management) was the cheapest drug in the group of ibandronic acid; its cost per course of treatment for three years was 11,405.88 UAH. Medicines on the basis of strontium ranelate were presented at the Ukrainian market only by one manufacturer. The results of the pharmacoeconomic analysis showed that ibandronate was the dominant method compared to strontium ranelate since it was more effective (62.0 % versus 41.0 %) and had a lower value for the cost-effectiveness ratio (18,396.58 UAH versus 150,602.56 UAH).

Conclusions. The data obtained suggest that the use of bisphosphonates, including ibandronate, is effective and cost-effective in menopausal osteoporosis.


Keywords


bisphosphonates; postmenopause; osteoporosis; strontium ranelate; cost – effectiveness; pharmacoeconomic analysis

References


Vertkin A.L., Arutyunov S.D., Sharov M.N. i dr. Osteoporoz v obschemeditsinskoy praktike. - Metod rekom. - M. – 2008. – 46 s.

Pasieshvili L. M. Osteoporoz — bezmolvnyiy kostnyiy «vor» // ShidnoEvropeyskiy zhurnal vnutrishnoYi ta simeynoYi meditsini. – 2015. – №1. – S. 19-23.

Povoroznyuk V.V., Grigoreva N.V. Menopauza i osteoporoz // Ekspres. - Kiev. – 2002. - 356 s.

Povoroznjuk V.V., Dzerovich N.I., Karasevskaya T.A. (2007) Bone mineral density in Ukrainian women of different age. Ann. New York Academy Sciences, 1119: 243–252.

Nasonov E.L. Profilaktika i lechenie osteoporoza: sovremennoe sostoyanie problemyi. // Russkiy meditsinskiy zhurnal. – 1998. – № 6. – S. 1176–1180.

Shishkova V.N. Profilaktika i terapiya osteoporoza. - Meditsinskie vesti. - 2011. - № 7. – S. 548.

Alekseeva L. I. Alendronat v lechenii osteoporoza// Consilium medicum. – 2012. – T.14, № 2. – S. 71-75.

Belovol A.N., Knyazkova I.I. Bisfosfonatyi v lechenii osteoporoza Klinicheskaya farmakologiya i terapIya. - 2014. № 23 (5). – S. 75-79.

Rizzoli R. Atlas of postmenopausal osteoporosis. — Current Medicine Group, 2005. — P. 25–90.

Yakovleva, L. V. Farmakoepidemiologichni doslidzhennya spozhivannya antibiotikiv iz grupi karbapenemiv / l. V. Yakovleva, N. O. Matyashova // Klinichna farmatsiya. - 2013. - № 1. - s. 4-7. - Bibliogr. : s. 6

.

Golovach I.Yu., Kochish A.Yu. Problema atipichnyih perelomov bedra na fone priema bisfosfonatov: strategicheskie i takticheskie voprosyi lecheniya osteoporoza. // Ratsionalnaya farmakoterapIya. - 2013. - № 4 (29). – S. 29-36.


GOST Style Citations


  1. Верткин А.Л., Арутюнов С.Д., Шаров М.Н. и др. Остеопороз в общемедицинской практике. - Метод реком. - М. – 2008. – 46 с.
  2. Пасиешвили Л. М. Остеопороз — безмолвный костный «вор» // Схiдноєвропейський журнал внутрiшньої та сiмейної медицини. –  2015. – № 1. – С. 19-23.
  3. Поворознюк В.В., Григорьева Н.В. Менопауза и остеопороз // Експрес. -  Киев. – 2002. - 356 с.

4. Povoroznjuk V.V., Dzerovich N.I., Karasevskaya T.A. (2007) Bone mineral density in Ukrainian women of different age. Ann. New York Academy Sciences, 1119: 243–252.

5. Насонов Е.Л. Профилактика и лечение остеопороза: современное состояние проблемы. // Русский медицинский журнал. – 1998. – № 6. – С. 1176–1180.

6. Шишкова В.Н. Профилактика и терапия остеопороза. -  Медицинские вести. -  2011. - №7. – С. 548.

7. Алексеева Л. И. Алендронат в лечении остеопороза// Consilium medicum. – 2012. – Т.14, №2. – С. 71-75.

8. Беловол А.Н., Князькова И.И. Бисфосфонаты в лечении остеопороза Клиническая фармакология и терапія. -  2014. № 23 (5). – С. 75-79.

9. Rizzoli R. Atlas of postmenopausal osteoporosis. — Current Medicine Group, 2005. — P. 25–90.

10. Яковлєва, Л. В. Фармакоепідеміологічні дослідження споживання антибіотиків із групи карбапенемів / Л. В. Яковлєва, Н. О. Матяшова // Клінічна фармація. - 2013. - № 1. - С. 4-7. - Бібліогр. : с. 6.

11.Головач И.Ю., Кочиш А.Ю. Проблема атипичных переломов бедра на фоне приема бисфосфонатов: стратегические и тактические вопросы лечения остеопороза. // Рациональная фармакотерапія. -  2013. - № 4 (29). – С. 29-36.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)